Dose Rationale of Nasal Glucagon in Japanese Pediatric Patients with Diabetes Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation

BACKGROUND: Nasal glucagon (NG) 3 mg is approved in Japan to treat hypoglycemia in pediatric patients with diabetes, but an NG clinical study has not been performed in Japanese children because of practical and ethical concerns. OBJECTIVE: The aim of this study is to support the dose rationale for N...

Descripción completa

Detalles Bibliográficos
Autores principales: Nasu, Risa, James, Douglas E., Chigutsa, Emmanuel, Garhyan, Parag, Nagai, Yukiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10097767/
https://www.ncbi.nlm.nih.gov/pubmed/36973474
http://dx.doi.org/10.1007/s40272-023-00565-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10097767/
https://www.ncbi.nlm.nih.gov/pubmed/36973474
http://dx.doi.org/10.1007/s40272-023-00565-y

Ejemplares similares